Welcome to our dedicated page for Xcelerate news (Ticker: XCRT), a resource for investors and traders seeking the latest updates and insights on Xcelerate stock.
Xcelerate Inc. reports company developments tied to medical technology, virtual health care and intellectual-property commercialization. Recent updates center on AfiyaSasa Africa LLC, the company’s majority-owned subsidiary focused on an AI-assisted patient portal and healthcare delivery model in Tanzania, including localization work, clinical-site evaluation and medical-technology research and development.
News also covers Xcelerate’s completed sale of its majority interest in the ESN Group, a transaction that moved the company away from the Ceramedx and Earth Natural Beauty skincare businesses. Other recurring themes include patent activity for surgical-tool camera technology, business funding, private-placement financing, auditor-related registration statement updates and broader shareholder communications.
Xcelerate, Inc. (OTC: XCRT) announced that Nobel Prize winner Dr. Barry Marshall discussed the company's mission to enhance medical technology during a global broadcast on ticker NEWS. Dr. Marshall, who serves on Xcelerate's Advisory Board, emphasized the benefits of working with an American public company, particularly in funding. He aims to identify investment opportunities in Australia for Xcelerate. CEO Michael O'Shea highlighted Dr. Marshall's contributions and the importance of increasing public awareness to support investment and medical communities.
Xcelerate, Inc. (OTC pink sheets: XCRT) announced signing a non-binding letter of intent (LOI) to explore a business combination with HS Pharmaceuticals, LLC, based in Greenville, SC. HS Pharmaceuticals has a platform of patented technologies focusing on immunotherapy alternatives and infection treatment. Xcelerate aims to leverage HS’s research and intellectual property through due diligence led by its team of clinicians and researchers. This strategic move underscores Xcelerate's commitment to innovative acquisitions in early-stage medical technology.
Xcelerate, a leader in early-stage medical technology, announced on May 3, 2021, the removal of the 'Yield' sign from its stock symbol by OTC Markets, achieving 'Pink Current Reporting' status. This change enhances corporate transparency and allows investors better access to company information. CEO Michael O'Shea expressed enthusiasm for this milestone, emphasizing ongoing efforts to maintain compliance and improve corporate standing. Additionally, the company is exploring innovative acquisitions in the patent and engineering sectors to further its growth.
Xcelerate, Inc. (OTC: XCRT) has launched a new website, www.xcelerate.global, highlighting its innovative role in integrating advanced engineering solutions with MedTech and clinical care. The website aims to communicate the company's mission, progress, and potential within the MedTech sector, serving as a platform for updates and news. CEO Michael O'Shea emphasized that the global domain reflects the company’s aspirations for international growth and collaboration. Xcelerate focuses on acquiring patents and engineering technologies and is committed to advancing early-stage medical technologies.
Xcelerate, Inc. (OTC: XCRT) announced on April 27, 2021, that Vincent C. du Vigneaud has joined its Advisory Board. With over 25 years of experience in financial analysis and capital structure, du Vigneaud is currently the Head of Non-Standard Investments at FinTrust Capital Advisors, which manages over $1.5 billion. His expertise in regulatory issues and business combinations is expected to support Xcelerate's development plans. The company aims to innovate acquisitions in medical technology and enhance clinical applications.
Xcelerate has announced a new ticker symbol, XCRT, following its name change from Union Dental Holdings. CEO Michael O'Shea stated that this step enhances the company's identity. The company is exploring acquisitions in the medtech sector to innovate clinical care but has not yet secured agreements. Notable additions to its advisory board include Nobel Laureate Dr. Barry Marshall and renowned neurosurgeon Dr. Dilan Ellegala, which may bolster Xcelerate's credibility in the medical field.